1
项与 REVO-UWD-00B 相关的临床试验A Clinical Study Evaluating the Safety and Efficacy of Universal BCMA-Targeted CAR-T (UWD-00B) Therapy for Refractory and Relapsed Multiple Myeloma
This study is a single-arm, investigator-initiated clinical trial. The primary objective is to evaluate the safety and preliminary efficacy of administering universal BCMA CAR-T cells to subjects with refractory and relapsed multiple myeloma. Eligible participants will undergo FC preconditioning after signing an informed consent form, followed by a one-time injection of universal UWD-00B cells to assess its safety and efficacy. Subjects will be hospitalized for a period, and after discharge, they will undergo periodic efficacy assessments and long-term survival follow-up for at least five years.
100 项与 REVO-UWD-00B 相关的临床结果
100 项与 REVO-UWD-00B 相关的转化医学
100 项与 REVO-UWD-00B 相关的专利(医药)
100 项与 REVO-UWD-00B 相关的药物交易